Distinguished in Lung Adenocarcinoma

Hong G. Zheng

Key Laboratory Of Carcinogenesis And Translational Research, 
Beijing, CN 
Distinguished in Lung Adenocarcinoma
Key Laboratory Of Carcinogenesis And Translational Research, 
Beijing, CN 
OverviewLocationsClinical Research

Overview

Hong Zheng practices in Beijing, China. Ms. Zheng is rated as a Distinguished expert by MediFind in the treatment of Lung Adenocarcinoma. Her top areas of expertise are Ovarian Cancer, Breast Cancer, Lung Adenocarcinoma, Mastectomy, and Liver Transplant.

Her clinical research consists of co-authoring 744 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 26 articles in the study of Lung Adenocarcinoma.

Gender
Female

Locations

Key Laboratory Of Carcinogenesis And Translational Research, Beijing, China
Other Locations
No. 138 Tongzipo Road, Changsha, 410013, China
81 Meishan Road, Hefei, 230022, China
NO. 1166, Dongfanghong West Road, Dezhou, 253014, China
81 Meishan Road, Hefei, China
No. 173 Taishan North Road, Deyang, 618000, China
No. 467 Zhongshan Road, Dalian, 116023, China
Chinese Academy Of Medical Sciences And Peking Union Medical College, Beijing, 100730, China
No. 137, Li Yu Shan Street, Ueruemqi, 830011, China
#100 Kexue Road, Zhengzhou, China
Union Hospital, Wuhan, 430022, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Drug
Study Drugs: Imlunestrant, Exemestane, Fulvestrant, Abemaciclib
Study Phase: Phase 3
A Open-label, Multicenter Phase II Study of TQB2450 Injection or Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer
A Open-label, Multicenter Phase II Study of TQB2450 Injection or Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer
Enrollment Status: Completed
Publish Date: May 28, 2025
Intervention Type: Drug
Study Drugs: TQB2450, Anlotinib
Study Phase: Phase 2
View 1 Less Clinical Trial

744 Total Publications

Recent Research Advances in Classification and Treatment of Primary Cutaneous Lymphoma--Review
Recent Research Advances in Classification and Treatment of Primary Cutaneous Lymphoma--Review
Journal: Zhongguo shi yan xue ye xue za zhi
Published: January 08, 2026

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Zheng's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 165 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile